CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy-Reference-Cited by-同舟云学术

CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy

Published:2017-04-26 Issue:7 Volume:52 Page:900-908
ISSN:8755-6863
Container-title:Pediatric Pulmonology
language:en
Short-container-title:Pediatr Pulmonol

Author:

Guerra Lorenzo¹,D'Oria Susanna²,Favia Maria¹,Castellani Stefano³,Santostasi Teresa⁴,Polizzi Angela M.⁴,Mariggiò Maria A.²,Gallo Crescenzio⁵,Casavola Valeria¹,Montemurro Pasqualina²,Leonetti Giuseppina⁴,Manca Antonio,Conese Massimo³^ORCID

Affiliation:

1. Department of Biosciences; Biotechnologies and Biopharmaceutics; University of Bari; Bari Italy

2. Department of Biomedical Sciences and Human Oncology; Section of General Pathology; University of Bari; Bari Italy

3. Department of Medical and Surgical Sciences; University of Foggia; Foggia Italy

4. Department of Biomedical and Human Oncology, Pediatrics Section; Cystic Fibrosis Regional Center, U.O. “B. Trambusti,” Policlinico; University of Bari; Bari Italy

5. Department of Clinical and Experimental Medicine; University of Foggia; Foggia Italy

Funder

Ministero della Salute

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology, and Child Health

Reference44 articles.

1. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation;Ramsey;N Engl J Med,2011

2. Efficacy and safety of ivacaftor in patients aged 6-11 years with cystic fibrosis with a G551D mutation;Davies;Am J Respir Crit Care Med,2013

3. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis;Rowe;Am J Respir Crit Care Med,2014

4. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST);McKone;Lancet Respir Med,2014

5. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation;De Boeck;J Cyst Fibros,2014

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Laboratory Tools to Predict CFTR Modulator Therapy Effectiveness and to Monitor Disease Severity in Cystic Fibrosis;Journal of Personalized Medicine;2024-01-13

2. Human epididymis protein 4 (HE4) plasma concentration inversely correlates with the improvement of cystic fibrosis lung disease in p.Phe508del-CFTR homozygous cases treated with the CFTR modulator lumacaftor/ivacaftor combination;Journal of Cystic Fibrosis;2023-11

3. Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies;Genes;2023-10-20

4. Neutrophil bactericidal activity and host defenses in cystic fibrosis: a narrative review;Journal of Thoracic Disease;2023-10

5. Multimodal analysis of granulocytes, monocytes, and platelets in patients with cystic fibrosis before and after Elexacaftor–Tezacaftor–Ivacaftor treatment;Frontiers in Immunology;2023-06-29